Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 91

Results For "US"

7516 News Found

Henkel joins MedTech Europe to drive innovation in the medical technology industry
News | September 20, 2023

Henkel joins MedTech Europe to drive innovation in the medical technology industry

Reinforces Henkel commitment to supporting customers and ecosystem in medical healthcare


Briefs: Caplin Steriles, Zydus  and APL Healthcare
Drug Approval | September 20, 2023

Briefs: Caplin Steriles, Zydus and APL Healthcare

Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients


Biovyn PVC to be used in sustainable prosthetics for the first time
News | September 20, 2023

Biovyn PVC to be used in sustainable prosthetics for the first time

Fillauer recently announced the launch of the first-ever bio-attributed prosthetic foot shell


Ojjaara approved in the US as the first and only treatment for myelofibrosis patients with anaemia
Drug Approval | September 19, 2023

Ojjaara approved in the US as the first and only treatment for myelofibrosis patients with anaemia

Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy


Galgotias University, HCL Healthcare to bring medical center to Greater Noida Campus
Healthcare | September 19, 2023

Galgotias University, HCL Healthcare to bring medical center to Greater Noida Campus

The partnership acknowledges the increasing mental health challenges faced by students in today's society


AstraZeneca Pharma India appoints Praveen Akkinepally as Business Unit Head - Oncology
People | September 16, 2023

AstraZeneca Pharma India appoints Praveen Akkinepally as Business Unit Head - Oncology

Currently, Praveen Akkinepally is the Head of Lung Cancer Commercialization, AstraZeneca Gaithersburg, MD, USA


Zydus receives final approval from USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System
Drug Approval | September 16, 2023

Zydus receives final approval from USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System

Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day had annual sales of US $330 million in the United States


Strides receives tentative USFDA approval for Dolutegravir/Lamivudine/Tenofovir Disproxil Fumurate tablets
Drug Approval | September 16, 2023

Strides receives tentative USFDA approval for Dolutegravir/Lamivudine/Tenofovir Disproxil Fumurate tablets

Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa


Strides receives tentative USFDA approval for Dolutegravir tablets
Drug Approval | September 15, 2023

Strides receives tentative USFDA approval for Dolutegravir tablets

The products will be manufactured at the company's facility in Bengaluru


Bajaj Healthcare announces receipt of EIR from USFDA
Drug Approval | September 14, 2023

Bajaj Healthcare announces receipt of EIR from USFDA

The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations